Artelo Biosciences (ARTL) Competitors $4.69 -0.13 (-2.70%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$4.70 +0.01 (+0.32%) As of 10/3/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARTL vs. KALA, IMNN, TXMD, SNSE, MRKR, ASBP, CARM, MBIO, HOOK, and LSBShould you be buying Artelo Biosciences stock or one of its competitors? The main competitors of Artelo Biosciences include KALA BIO (KALA), Imunon (IMNN), TherapeuticsMD (TXMD), Sensei Biotherapeutics (SNSE), Marker Therapeutics (MRKR), Aspire Biopharma (ASBP), Carisma Therapeutics (CARM), Mustang Bio (MBIO), HOOKIPA Pharma (HOOK), and LakeShore Biopharma (LSB). These companies are all part of the "pharmaceutical products" industry. Artelo Biosciences vs. Its Competitors KALA BIO Imunon TherapeuticsMD Sensei Biotherapeutics Marker Therapeutics Aspire Biopharma Carisma Therapeutics Mustang Bio HOOKIPA Pharma LakeShore Biopharma KALA BIO (NASDAQ:KALA) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership. Which has more risk & volatility, KALA or ARTL? KALA BIO has a beta of -2.1, meaning that its stock price is 310% less volatile than the S&P 500. Comparatively, Artelo Biosciences has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Do analysts recommend KALA or ARTL? KALA BIO presently has a consensus target price of $20.38, suggesting a potential upside of 1,223.05%. Artelo Biosciences has a consensus target price of $24.00, suggesting a potential upside of 411.73%. Given KALA BIO's higher probable upside, research analysts plainly believe KALA BIO is more favorable than Artelo Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KALA BIO 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Artelo Biosciences 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.40 Is KALA or ARTL more profitable? Artelo Biosciences' return on equity of -497.68% beat KALA BIO's return on equity.Company Net Margins Return on Equity Return on Assets KALA BION/A -686.43% -76.81% Artelo Biosciences N/A -497.68%-213.76% Do institutionals and insiders hold more shares of KALA or ARTL? 24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are owned by institutional investors. 8.3% of KALA BIO shares are owned by company insiders. Comparatively, 5.8% of Artelo Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has higher earnings and valuation, KALA or ARTL? Artelo Biosciences has lower revenue, but higher earnings than KALA BIO. Artelo Biosciences is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKALA BIO$3.89M2.78-$38.51M-$6.79-0.23Artelo BiosciencesN/AN/A-$9.83M-$19.05-0.25 Does the media favor KALA or ARTL? In the previous week, KALA BIO had 31 more articles in the media than Artelo Biosciences. MarketBeat recorded 38 mentions for KALA BIO and 7 mentions for Artelo Biosciences. Artelo Biosciences' average media sentiment score of 0.04 beat KALA BIO's score of -0.27 indicating that Artelo Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KALA BIO 1 Very Positive mention(s) 2 Positive mention(s) 12 Neutral mention(s) 6 Negative mention(s) 2 Very Negative mention(s) Neutral Artelo Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryKALA BIO beats Artelo Biosciences on 8 of the 14 factors compared between the two stocks. Get Artelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARTL vs. The Competition Export to ExcelMetricArtelo BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.30M$3.36B$6.13B$10.58BDividend YieldN/A2.28%5.66%4.69%P/E Ratio-0.2522.1486.8826.70Price / SalesN/A461.34608.05229.32Price / CashN/A46.3226.3031.09Price / Book0.889.9012.536.57Net Income-$9.83M-$52.45M$3.30B$276.78M7 Day Performance-14.88%5.22%4.28%2.42%1 Month Performance3.99%10.61%6.90%8.63%1 Year Performance-29.91%25.03%70.54%31.60% Artelo Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARTLArtelo Biosciences2.5172 of 5 stars$4.69-2.7%$24.00+411.7%-29.9%$3.30MN/A-0.255Short Interest ↑KALAKALA BIO4.1284 of 5 stars$1.78-13.4%$20.38+1,047.9%-71.5%$12.53M$3.89M-0.2630Analyst DowngradeInsider TradeShort Interest ↑Analyst RevisionGap DownHigh Trading VolumeIMNNImunon2.0592 of 5 stars$5.10-1.5%$232.50+4,458.8%-66.9%$12.44MN/A-0.3930TXMDTherapeuticsMD0.375 of 5 stars$1.08-0.5%N/A-34.7%$12.44M$1.76M0.00420Negative NewsShort Interest ↑SNSESensei Biotherapeutics4.1391 of 5 stars$9.27-2.9%$55.00+493.3%-6.1%$11.68MN/A-0.4440Positive NewsGap DownMRKRMarker Therapeutics4.0298 of 5 stars$0.88-4.9%$13.17+1,394.5%-65.9%$11.37M$6.59M-0.6460Positive NewsShort Interest ↓ASBPAspire BiopharmaN/A$0.23-26.7%N/AN/A$11.35MN/A0.00N/ANews CoverageGap DownCARMCarisma Therapeutics2.471 of 5 stars$0.27-7.7%$1.93+613.0%-72.4%$11.28M$19.63M-0.1720News CoverageShort Interest ↑MBIOMustang Bio0.9317 of 5 stars$1.55-1.6%N/A-85.5%$11.19MN/A-0.02100Positive NewsShort Interest ↓HOOKHOOKIPA Pharma2.979 of 5 stars$0.91-0.2%$4.50+395.6%-77.1%$11.07M$9.35M-0.16160LSBLakeShore Biopharma0.7628 of 5 stars$0.53-33.0%N/A-90.3%$11.01M$85.67M0.00773High Trading Volume Related Companies and Tools Related Companies KALA BIO Alternatives Imunon Alternatives TherapeuticsMD Alternatives Sensei Biotherapeutics Alternatives Marker Therapeutics Alternatives Aspire Biopharma Alternatives Carisma Therapeutics Alternatives Mustang Bio Alternatives HOOKIPA Pharma Alternatives LakeShore Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARTL) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artelo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARTL Stock Alerts